CANbridge Pharmaceuticals Inc. and Mirum Pharmaceuticals signed an exclusive license agreement for the development, commercialization and manufacture, under certain conditions, of maralixibat (CAN108) in Greater China last year. Under the terms of the agreement, CANbridge has the right to develop and commercialize CAN108 for three indications: Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC) and biliary atresia (BA) in Greater China.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.305 HKD | 0.00% | -1.61% | -69.19% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-69.19% | 16.56M | |
+14.56% | 9.82B | |
-7.87% | 5.49B | |
+12.50% | 4.21B | |
+18.09% | 3.66B | |
+44.14% | 2.93B | |
-19.01% | 2.54B | |
-20.66% | 2.35B | |
+16.83% | 1.85B | |
-0.50% | 1.64B |
- Stock
- Equities
- Stock CANbridge Pharmaceuticals Inc. - Hong Kong S.E.
- News CANbridge Pharmaceuticals Inc.
- CANbridge Pharmaceuticals Inc. and Mirum Pharmaceuticals Sign an Exclusive License Agreement for the Development, Commercialization and Manufacture Under Certain Conditions of Maralixibat